A Study to Examine the Potential Effect of Rifampin on the Pharmacokinetics of Neratinib When Administered Concomitantly to Healthy Subjects.

Trial Profile

A Study to Examine the Potential Effect of Rifampin on the Pharmacokinetics of Neratinib When Administered Concomitantly to Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

At a glance

  • Drugs Neratinib; Rifampicin
  • Indications Advanced breast cancer; Early breast cancer; Non-small cell lung cancer; Solid tumours; Tuberculosis
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 11 May 2012 Additional company (Puma Biotechnology) added in association as reported by ClinicalTrials.gov.
    • 11 May 2012 Planned initiation date changed from 1 May 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top